FHA
GLMD icon

Flagship Harbor Advisors’s Galmed Pharmaceuticals GLMD Stock Holding History

Flagship Harbor Advisors’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2
Closed -$1K – 993
2020
Q3 		$1K Hold
2
– – ﹤0.01% 1814
2020
Q2 		$1K Hold
2
– – ﹤0.01% 1901
2020
Q1 		$1K Hold
2
– – ﹤0.01% 1736
2019
Q4 		$2K Hold
2
– – ﹤0.01% 1710
2019
Q3 		$1K Hold
2
– – ﹤0.01% 1749
2019
Q2 		$2K Hold
2
– – ﹤0.01% 1675
2019
Q1 		$2K Hold
2
– – ﹤0.01% 1667
2018
Q4 		$2K Hold
2
– – ﹤0.01% 1634
2018
Q3 		$4K Hold
2
– – ﹤0.01% 1748
2018
Q2 		$3K Buy
+2
New +$2.9K ﹤0.01% 1767

Other funds holding GLMD

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Flagship Harbor Advisors's GLMD Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Galmed Pharmaceuticals (GLMD) in Q4 2020, closing a stake of 2 shares — an estimated $1K sold.

Flagship Harbor Advisors first reported a position in GLMD in Q2 2018 and held it in 10 quarters. The position peaked at $4K in Q3 2018. 21 funds tracked by Wall St. Rank hold GLMD as of Q4 2020.

  • Flagship Harbor Advisors reported no remaining Galmed Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Flagship Harbor Advisors sold 2 Galmed Pharmaceuticals shares in Q4 2020, an estimated $1K.
  • Flagship Harbor Advisors first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 10 quarters.
  • Flagship Harbor Advisors's Galmed Pharmaceuticals position peaked at $4K in Q3 2018.
  • 21 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.